VTGN VistaGen Therapeutics Inc

Price (delayed)

$3.92

Market cap

$105.94M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.52

Enterprise value

-$11.11M

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and ...

Highlights
VistaGen Therapeutics's EPS has soared by 82% YoY and by 57% from the previous quarter
The net income has surged by 50% year-on-year and by 8% since the previous quarter
VTGN's quick ratio is down by 23% since the previous quarter
The equity has decreased by 7% QoQ

Key stats

What are the main financial stats of VTGN
Market
Shares outstanding
27.03M
Market cap
$105.94M
Enterprise value
-$11.11M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.93
Price to sales (P/S)
71.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-10.44
Earnings
Revenue
$1.06M
EBIT
-$29.36M
EBITDA
-$28.79M
Free cash flow
-$25.87M
Per share
EPS
-$1.52
Free cash flow per share
-$1.34
Book value per share
$4.23
Revenue per share
$0.05
TBVPS
$6.39
Balance sheet
Total assets
$123.65M
Total liabilities
$9.37M
Debt
$2.12M
Equity
$114.29M
Working capital
$115.55M
Liquidity
Debt to equity
0.02
Current ratio
23.55
Quick ratio
23.26
Net debt/EBITDA
4.07
Margins
EBITDA margin
-2,705.8%
Gross margin
100%
Net margin
-2,759.6%
Operating margin
-3,103.5%
Efficiency
Return on assets
-37.6%
Return on equity
-41.9%
Return on invested capital
-918.5%
Return on capital employed
-24.8%
Return on sales
-2,759.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VTGN stock price

How has the VistaGen Therapeutics stock price performed over time
Intraday
7.1%
1 week
0.26%
1 month
17.01%
1 year
110.75%
YTD
-23.74%
QTD
12.64%

Financial performance

How have VistaGen Therapeutics's revenue and profit performed over time
Revenue
$1.06M
Gross profit
$1.06M
Operating income
-$33.02M
Net income
-$29.36M
Gross margin
100%
Net margin
-2,759.6%
The net income has surged by 50% year-on-year and by 8% since the previous quarter
The company's operating income rose by 44% YoY and by 2.6% QoQ
The company's net margin rose by 10% QoQ
The operating margin is up by 4.6% since the previous quarter

Growth

What is VistaGen Therapeutics's growth rate over time

Valuation

What is VistaGen Therapeutics stock price valuation
P/E
N/A
P/B
0.93
P/S
71.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-10.44
VistaGen Therapeutics's EPS has soared by 82% YoY and by 57% from the previous quarter
The price to book (P/B) is 38% lower than the last 4 quarters average of 1.5
The equity has decreased by 7% QoQ
VistaGen Therapeutics's revenue has increased by 2.1% QoQ

Efficiency

How efficient is VistaGen Therapeutics business performance
The ROE has soared by 81% YoY and by 42% from the previous quarter
The company's return on assets has surged by 76% YoY and by 39% QoQ
The company's return on invested capital has surged by 58% YoY
VistaGen Therapeutics's ROS has increased by 10% from the previous quarter

Dividends

What is VTGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VTGN.

Financial health

How did VistaGen Therapeutics financials performed over time
The current ratio has decreased by 23% from the previous quarter
VTGN's quick ratio is down by 23% since the previous quarter
The company's debt is 98% lower than its equity
VTGN's debt to equity has dropped by 91% year-on-year
The company's debt fell by 22% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.